Signature Estate & Investment Advisors LLC Purchases 381 Shares of iShares Biotechnology ETF (NASDAQ:IBB)

Signature Estate & Investment Advisors LLC grew its position in shares of iShares Biotechnology ETF (NASDAQ:IBB) by 4.3% in the 4th quarter, HoldingsChannel reports. The fund owned 9,282 shares of the financial services provider’s stock after buying an additional 381 shares during the period. Signature Estate & Investment Advisors LLC’s holdings in iShares Biotechnology ETF were worth $1,227,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of IBB. BNP Paribas Financial Markets raised its holdings in iShares Biotechnology ETF by 29.3% during the third quarter. BNP Paribas Financial Markets now owns 2,380,229 shares of the financial services provider’s stock worth $346,561,000 after buying an additional 538,899 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in shares of iShares Biotechnology ETF in the 4th quarter worth about $55,010,000. Healthcare of Ontario Pension Plan Trust Fund lifted its position in iShares Biotechnology ETF by 32.9% in the 3rd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 663,000 shares of the financial services provider’s stock valued at $96,533,000 after acquiring an additional 164,000 shares in the last quarter. Aprio Wealth Management LLC acquired a new position in iShares Biotechnology ETF during the 4th quarter valued at about $18,476,000. Finally, Generali Investments CEE investicni spolecnost a.s. bought a new stake in iShares Biotechnology ETF during the 4th quarter worth approximately $11,370,000. 62.45% of the stock is owned by institutional investors and hedge funds.

iShares Biotechnology ETF Stock Down 1.7 %

Shares of iShares Biotechnology ETF stock opened at $132.97 on Wednesday. iShares Biotechnology ETF has a 52 week low of $123.60 and a 52 week high of $150.57. The business has a 50 day moving average price of $136.28 and a 200-day moving average price of $139.16. The company has a market cap of $6.28 billion, a PE ratio of 27.83 and a beta of 0.84.

iShares Biotechnology ETF Increases Dividend

The business also recently declared a dividend, which was paid on Friday, March 21st. Investors of record on Tuesday, March 18th were given a $0.1212 dividend. This is a positive change from iShares Biotechnology ETF’s previous dividend of $0.06. The ex-dividend date of this dividend was Tuesday, March 18th.

iShares Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.